A national survey of 157 patients with non-small cell lung cancer found that all groups prioritized extending life, but treatment preferences, including concerns about side effects and quality-of-life tradeoffs, differed across racial and ethnic groups.

AI’s very design encourages a small number of users to go down delusional rabbit holes, researchers argue in a preprint article.

In lupus patients, latent Epstein-Barr virus can reprogram B cells and send the body’s immune response into overdrive, resulting in widespread inflammation.

Drug and hospital prices are top employer healthcare concerns as costs rise, but some employers are unable to access their data, finds a survey by the National Alliance of Healthcare Purchaser Coalitions.

World AIDS Day highlights ongoing challenges in HIV prevention and treatment, urging renewed commitment to end the epidemic and support affected communities.

Drug approvals this year have reflected the trend in clinical development of biologics shifting from intravenous to subcutaneous administration, offering shorter injection times, home use, and cost savings for cancer, Alzheimer’s, and inflammatory diseases.

A recent study revealed that patients with hidradenitis suppurativa experience quicker treatment failure when switching to biosimilar adalimumab compared to the original.

A new report reveals the heavy personal and economic toll of MS and recommends more complete, patient focused approaches to measuring and managing the disease.

Kamuvudines are a new class of drugs that are derived from the anti-HIV nucleoside reverse transcriptase inhibitors. They are designed to inhibit the inflammasome, part of the innate immune system that is triggered in geographic atrophy.